FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cells patents



      
           
This page is updated frequently with new Cells-related patent applications. Subscribe to the Cells RSS feed to automatically get the update: related Cells RSS feeds. RSS updates for this page: Cells RSS RSS


Xenograft model of human bone metastatic prostate cancer

Xenograft model of human bone metastatic prostate cancer

Xenograft model of human bone metastatic prostate cancer

Computer system and management system

Date/App# patent app List of recent Cells-related patents
10/09/14
20140304859
 Polypeptides having endoglucanase activity and polynucleotides encoding same patent thumbnailPolypeptides having endoglucanase activity and polynucleotides encoding same
Provided are isolated polypeptides having endoglucanase activity and polynucleotides encoding the polypeptides. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
10/09/14
20140304848
 Genes and uses for plant improvement patent thumbnailGenes and uses for plant improvement
This invention provides transgenic plant cells with recombinant dna for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. This invention also provides transgenic plants and progeny seed comprising the transgenic plant cells where the plants are selected for having an enhanced trait selected from the group of traits consisting of enhanced water use efficiency, enhanced cold tolerance, increased yield, enhanced nitrogen use efficiency, enhanced seed protein and enhanced seed oil.
10/09/14
20140304844
 Xenograft model of human bone metastatic prostate cancer patent thumbnailXenograft model of human bone metastatic prostate cancer
The disclosure herein provides a bone metastasis-derived prostate cancer xenograft model. The disclosure also provides methods for making a bone metastasis-derived prostate cancer xenograft model.
10/09/14
20140304451
 Computer system and management system patent thumbnailComputer system and management system
A storage system, which comprises multiple memory cells and a storage controller, wherein the storage controller manages cell mode information, which either directly or indirectly denotes the number of bits to be stored in multiple memory cells. The cell mode information can be changed in accordance with a request from a management system..
10/09/14
20140304278
 Dynamic maps for exploring and browsing of images patent thumbnailDynamic maps for exploring and browsing of images
A method of mapping a collection of images, or other higher dimensional items including text documents, and three-and-higher dimensional objects, onto a navigable grid for browsing via a user interface comprises obtaining for each of the images a list of nearest neighbor images and similarity scores for each nearest neighbor; placing a first image on a cell within a grid; from a respective list of nearest neighbors of said first image, finding images that maximize a compatibility score with images already placed on the grid and placing resulting images on neighboring cells; and continuing to place further images on the grid until all cells visible to a user are filled with images. As the user pans or zooms the grid, more cells move into the visible area of the screen and are filled with images in the same way..
10/09/14
20140304012
 Insurance policies for stem cells depositors and methods for providing same patent thumbnailInsurance policies for stem cells depositors and methods for providing same
A method, apparatus and computer program product for generating and applying insurance policies intended to guarantee sufficient amounts of available, viable stem cells to policy holders in case the policy holders are in need of stem cell therapy. An individual may deposit stem cells and give consent to allocate at least some of the stem cells deposited by said individual for public use, and in return be entitled to receive viable stem cells deposited by another individual in case of need..
10/09/14
20140303944
 Predictive position decoding patent thumbnailPredictive position decoding
A method and apparatus for position decoding of three dimensional mesh models are described including predicting a symbol probability of a non-empty-child-cell cl,k, where cl,k denotes the kth cell at layer l, wherein the symbol probability is estimated based on an accuracy of a fitted plane p, decoding the non-empty-child-cell responsive to the received predicted probability of the non-empty-child-cell, subdividing the non-empty-child-cell, if the non-empty-child-cell has more than one vertex, determining if there are more unprocessed non-empty-child-cells at layer l, determining if a lowest layer of non-empty-child-cells has been reached, if there are no more unprocessed non-empty-child-cells at layer l and regenerating the three dimensional mesh model, if the lowest layer of non-empty-child-cells has been reached.. .
10/09/14
20140303727
 Device for ear drum repair patent thumbnailDevice for ear drum repair
A device for use in the repair of an ear drum in a subject in need of such treatment, said device: having a tensile strength youngs modulus between approximately 12.5 and 40 mpa; comprising one or more membrane layers, wherein at least one membrane layer comprises a plurality of pores; and wherein the device can support proliferation, migration and/or adhesion of cells selected from the group comprising at least any one or more of: keratinocytes, fibroblasts, vascular cells, mucosal epithelial cells, and stem cells.. .
10/09/14
20140303701
 Low temperature hyperthermia system for therapeutic treatment of invasive agents patent thumbnailLow temperature hyperthermia system for therapeutic treatment of invasive agents
The low temperature hyperthermia system illuminates nano-particles, which are implanted in a living organism at the locus of the cancer or into the cancer cells, with a precisely determined energy field. This energy field ensures that the optimal cancer cell and cancer stem cell destruction temperature of 42° c.
10/09/14
20140303613
 System and method for energy delivery to a tissue using an electrode array patent thumbnailSystem and method for energy delivery to a tissue using an electrode array
Devices, systems, and related methods for electric fields delivery for preferential destruction of cancerous cells and tissue ablation.. .
10/09/14
20140303590
Method and composition for hyperthermally treating cells
A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.. .
10/09/14
20140303557
Electrical power source for an intravenous fluid heating system
An apparatus heats fluids. A number of lithium-ion cells are positioned within a housing.
10/09/14
20140303546
Laser assisted delivery of functional cells, peptides and nucleotides
The present invention relates to methods, uses, systems and kits for laser-assisted delivery of at least one bioactive agent to a subject. Specifically, laser light is used to create channel(s) in tissue of the subject, and the bioactive agent (s) is applied to the opening of the channel(s).
10/09/14
20140303542
Method and device for treating cancer
A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions.
10/09/14
20140303526
Selective removal of cells having accumulated agents
A method of treating a condition associate with accumulation of an agent in cells in a patient includes exposing the cells to ultrasound, to selectively kill or induce apoptosis in the cells. The cells include the accumulated agent..
10/09/14
20140303525
Method and device for non-invasive acoustic stimulation of stem cells and progenitor cells in a patient
The present invention provides a method for non-invasive acoustic stimulation of stem cells and/or progenitor cells in a patient. The invention also provides a device for non-invasive stimulation of stem cells and/or progenitor cells in the patient by generating and delivering acoustic waves of a suitable frequency and intensity to the stem cells and/or progenitor cells.
10/09/14
20140303517
Cord blood perfusion and collection system
An embodiment in accordance with the present invention provides a device and method for collecting cord blood from the umbilical cord and placenta. The device includes a vascular access device, a portable tray container, and a perfusion pump device.
10/09/14
20140303432
Medical devices incorporating functional adhesives
A method for treating a wound or defect at a surgical target site using a minimally invasive surgical procedure is provided which includes utilizing a surgical access device such as a port or a catheter having a plurality of reactive members of a specific binding pair releasably contained on a surface of the access device, the reactive members having affinity for binding a cellular component of tissue cells located at the target site; contacting the surface of the access device with the tissue cells, wherein upon contact of the reactive members on the surface of the access device with the tissue cells, the reactive members are released from the surface of the access device and bind to the tissue; providing a tissue repair member having secured thereto a plurality of complementary reactive members of the specific binding pair; and applying the tissue repair member to the tissue, wherein upon contact of the complementary reactive members on the surface of the tissue repair member with the reactive members on the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus bonding the tissue repair member to the tissue. A surgical access device for use in minimally invasive surgery is provided which includes a plurality of reactive members of a specific binding pair releasably contained on a surface of the access device, the reactive members having an affinity for binding a cellular component of tissue cells and another affinity for binding complementary members of the specific binding pair..
10/09/14
20140303355
Humanized anti-factor d antibodies and uses thereof
The invention relates to humanized anti-human factor d monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease..
10/09/14
20140303346
Method for silk fibroin gelation using sonication
This invention provides for a process of rapidly forming silk fibroin gelation through ultrasonication. Under the appropriate conditions, gelation can be controlled to occur within two hours after the ultrasonication treatment.
10/09/14
20140303335
Diketopyrrolopyrrole polymers for use in organic semiconductor devices
The present invention relates to polymers comprising one or more (repeating) unit(s) of the formula (i) which are characterized in that ar1 and ar1′ are independently of each other are an annulated (aromatic) heterocyclic ring system, containing at least one thiophene ring, which may be optionally substituted by one, or more groups, and their use as organic semiconductor in organic devices, especially in organic photovoltaics (solar cells) and photodiodes, or in a device containing a diode and/or an organic field effect transistor. The polymers according to the invention have excellent solubility in organic solvents and excellent film-forming properties.
10/09/14
20140303256
Pharmaceutical composition comprising fluoxetine as an active ingredient for preventing or treating blood-brain disorders
The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder comprising fluoxetine as an active ingredient. More particularly, fluoxetine inhibits the expressions of matrix metalloproteinase(mmp)-2, mmp-9, and mmp-12, which are reported to be related to blood-brain barrier (bbb) disruption and inflammatory reaction after spinal cord injury, specifically inhibits the activations of mmp-2 and mmp-9, inhibits the decomposition of zo-1, the most representative tight junction protein, so as to maintain tight junction between endothelial cells and to protect blood-brain barrier thereby, inhibits the increase of blood-brain barrier permeability, and inhibits the expressions of chemoattractants of blood cells, such as cxcl-1, cxcl-2, ccl-2, ccl-3 and ccl-4 so as to reduce inflow of blood into spinal cord and recover exercise function which has been deteriorated by spinal cord injury.
10/09/14
20140303251
Methods of treating acute kidney injury with retinoic acid
The present invention provides, in one embodiment, a method of inhibiting apoptosis in kidney epithelial cells after acute injury by modulating/inhibiting nur77 induction/expression or function/activity in the cells. The invention further provides a method of preventing or treating an acute kidney injury in a subject in need thereof, comprising administering to the subject an effective amount of a retinoic acid or retinoic acid derivative, and a method of preserving a kidney for transplant, comprising contacting the kidney with a solution that comprises a retinoic acid or a, retinoic acid derivative..
10/09/14
20140303242
Sparstolonin b based pharmaceutical agent to treat pathological angiogensis
Anti-angiogenesis methods and compositions are described. The anti-angiogenic effect is provided by application of sparstolonin b or a derivative thereof to endothelial cells.
10/09/14
20140303239
Telomerase mediated telomere altering compounds
The present disclosure is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogs thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells..
10/09/14
20140303232
Lipids and lipid compositions for the delivery of active agents
Or a pharmaceutically acceptable salt thereof, wherein r1-r4, l and x are defined herein. The compounds of formula (i) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues..
10/09/14
20140303223
Composition and method for muscle repair and regeneration
The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of rar agonists or stem cells that are pretreated with contact with a rar agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising rar agonist treated stem cells and methods of use of said cells for muscle repair or regeneration.
10/09/14
20140303212
Method for treating neurodegeneration using a p38mapk inhibitor
Ataxia-telangiectasia (a-t) is a progressive degenerative disorder that results in major neurological disability. In a-t patients, necropsy has revealed atrophy of all cerebellar cortical layers with extensive purkinje and granular cell loss.
10/09/14
20140303191
Use of inhibitors of bruton's tyrosine kinase (btk)
Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible btk inhibitor..
10/09/14
20140303188
Substituted cyclopenta pyrimidine bicyclic compounds having antitmitotic and/or antitumor activity and methods of use thereof
And pharmaceutically acceptable salts, prodrugs, solvates, and hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, such as for example p-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells..
10/09/14
20140303134
Platinum compounds that inhibit constitutive stat3 signaling and induce cell cycle arrest and apoptosis of malignant cells
The subject invention concerns a compound and compositions having activity as an inhibitor of stat3 protein and methods of using the compound and compositions. In one embodiment, a compound of the invention has the structure shown in formula i, formula ii, or formula iii.
10/09/14
20140303133
Markers of triple-negative breast cancer and uses thereof
In one aspect provided herein are methods of determining a triple negative breast cancer (tnbc) subtype in an individual in need thereof comprising determining expression of one or more genes in one or more tnbc cells of the individual; and comparing the expression of the one or more genes in the tnbc cells with the expression of the one or more genes in a control. In another aspect, the methods are directed to methods of determining a treatment protocol for the tnbc patient based on the tnbc subtype.
10/09/14
20140303103
Carbonic anhydrase ix-related markers and use thereof
The present disclosure provides methods for detecting the presence of a cancer stem cell and their use in cancer prognosis, evaluating risk of cancer metastasis, identifying or validating drug candidates, and determining treatment efficacy. It also provides kits useful for detecting the presence of cancer stem cells as well as methods of treating cancer using caix inhibitors..
10/09/14
20140303093
Micro-utrophin polypeptides and methods
Described herein are polypeptides, polynucleotides and methods involving a μ-utrophin region or an anti-dystrophinopathic fragment thereof operationally linked to a second region effective to transduce the fusion protein into mammalian muscle cells.. .
10/09/14
20140303085
Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5fu, bortezomib, doxorubicin, cisplatin, or any combination thereof.
10/09/14
20140303081
Apoptosis-targeting nanoparticles
Nanoparticles include a core and one or more targeting moieties, as well as one or more contrast agents or one or more therapeutic agents. The contrast agents or therapeutic agents may be contained or embedded within the core.
10/09/14
20140303079
Delaying the progression of diabetes
Type-1 diabetes (t1 d) results from the autoimmune recognition of insulin producing β-cells within the pancreatic islet. The present application discloses a new protein, islet homeostasis protein (ihop), that has a role in glucagon synthesizing-cell functions, and in post-onset t1 d islet differential expression of ihop.
10/09/14
20140303078
Modulation of pancreatic beta cell proliferation
Work described herein provides, in one embodiment, a method for increasing proliferation or replication of pancreatic beta cells in a subject in need thereof, comprising administering to said subject an effective amount of an agent that increases the level or activity of hepatocellular carcinoma-associated protein td26 (td26), thereby increasing proliferation or replication of pancreatic beta cells. Such an agent may function by, for example, increasing the level of active td26 in the subject or by increasing the functional activity of td26 in the subject..
10/09/14
20140303077
Albumin fusion proteins
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells.
10/09/14
20140303036
Nucleic acid assembly system
The present invention relates to a method for the preparation of a library of host cells, a plurality of which comprise an assembled polynucleotide at a target locus, which method comprises: (a) providing a plurality of polynucleotides comprising two or more polynucleotide subgroups, wherein: (i) a plurality of polynucleotides in each polynucleotide subgroup comprises sequence encoding a peptide or polypeptide and/or a regulatory sequence; (ii) a plurality of peptides or polypeptides encoded by, or a plurality of regulatory sequences comprised within, each polynucleotide subgroup share an activity and/or function; (iii) at least one polynucleotide subgroup comprises at least two non-identical polynucleotide species; (iv) a plurality of polynucleotides of each polynucleotide subgroup comprises sequence enabling homologous recombination with a plurality of polynucleotides from one or more other polynucleotide subgroups; and (v) a plurality of polynucleotides in two polynucleotide subgroups comprise a nucleotide sequence enabling homologous recombination with a target locus in host cells; and (b) assembling the plurality of polynucleotides at the target locus by homologous recombination in vivo in host cells, thereby to generate a library of host cells, a plurality of which comprise an assembled polynucleotide at the target locus. The assembled polynucleotides may be recovered, thereby to prepare a library of nucleic acids..
10/09/14
20140303029
Genetic alterations in glioma
Methods and genetic sequences are described for use in determining the diagnosis, subtype, prognosis, and disease course of high-grade gliomas, such as glioblastoma multiforme. One such method includes determining increased expression of at least one gene on a chromosome segment in cells of the glioma, the segment being 17:57,851,812-17:57,973,757; 7:127,892,509-7:127,947,649; 12:33,854-12:264,310; or 19:33,329,393-19:35,322,055; and estimating, based on the expression, a predicted length of survival, a probability of survival, or a predicted response to a therapy for the glioma..
10/09/14
20140303028
Genomic diagnostics using circulating endothelial cells
Circulating endothelial cells are isolated from patient blood and gene expression of the cells is analyzed to assess a medical condition or the tissue of origin of the cell. Kits for conducting the method are also provided..
10/09/14
20140302976
Centrifuge
Centrifuges are useful to, among other things, remove red blood cells from whole blood and retain platelets and other factors in a reduced volume of plasma. Platelet rich plasma (prp) and or platelet poor plasma (ppp) can be obtained rapidly and is ready for immediate injection into the host.
10/09/14
20140302880
Radio access network defined paging area
A method of facilitating paging in a wireless communications network includes generating, at a radio access network (ran) element of the communications network, a select paging area for a ue which is improved or optimized by taking ran and ue specific information into account, the select paging area including information indicating one or more cells from among cells of the communications network to which paging messages are to be sent when paging the ue; and sending the select paging area from the ran element to a core network (cn) element of the communications network.. .
10/09/14
20140302863
Virtual cell management for interference suppression and interference cancellation in lte
In some aspects, a method for performing wireless communication includes configuring a set of virtual cells for user equipments (ues). One or more virtual cells of the set is associated with at least one set of parameters.
10/09/14
20140302860
Wireless communications system and method
The invention is directed to a mobile communications system having improved spectral efficiency. The invention is further directed to methods and apparatus to achieve this improved spectral efficiency.
10/09/14
20140302857
Radio parameter control system, radio parameter control apparatus, radio base station, radio terminal, radio parameter control method and program
The present invention is a radio parameter control system for deciding a radio parameter of radio cells, using radio terminal measurement information measured by a radio terminal, the radio parameter control system comprising: radio terminal movement judgment means configured to judge whether largeness of movement of the radio terminal is within a predetermined range; and radio parameter decision means configured to distinguish between the radio terminal measurement information reported by the radio terminal of which largeness of the movement is within the predetermined range and the radio terminal measurement information reported by the radio terminal of which largeness of the movement is beyond the predetermined range, and decide the radio parameter of the radio cells.. .
10/09/14
20140302821
Security handling for multi frequency band
Systems, methods, apparatuses, and computer program products for security handling in, for example, cells that support multiple frequency band indication are provided. One method includes receiving, for example by a source evolved node b (enb) configured to communicate with a user equipment, a multiple frequency band indicator (mfbi) list, the multiple frequency band indicator (mfbi) list comprising at least one frequency band number listed in the same order of priority as broadcast by a target enb.
10/09/14
20140302655
Non-volatile memory device with vertical memory cells and method for fabricating the same
A non-volatile memory device includes a plurality of gate electrodes stacked over a semiconductor substrate and stretched in a first direction along the semiconductor substrate and a plurality of junction layers having a first region protruding from the semiconductor substrate and crossing the gate electrodes and a second region formed between the gate electrodes.. .
10/09/14
20140302648
Charge storage nodes with conductive nanodots
Methods of forming memory cells having conductive nanodots over a charge storage material are useful in non-volatile memory devices and electronic systems.. .
10/09/14
20140302634
Apparatus and method for producing solar cells
A method and apparatus for forming a solar cell. The apparatus includes a housing defining a vacuum chamber and a rotatable substrate apparatus configured to hold a plurality of substrates on a plurality of surfaces.
10/09/14
20140302633
Selective chemical etching process
The present invention relates to a process for selective wet chemical etching of a thin-film substrate comprising a cigs surface layer. The present invention also relates to a process for producing cells in series for thin-film photovoltaic modules, which process implements the selective wet chemical etching process according to the invention.
10/09/14
20140302609
Polydnavirus delivery constructs
Provided herein are methods of producing a genetically modified cell by introducing a polydnavirus delivery construct to a target cell. The polydnavirus delivery construct can comprise an exogenous nucleic acid to form a genetically modified cell comprising the exogenous nucleic acid.
10/09/14
20140302607
Polymer based polynucleotide transfection agents
The present invention provides a methodology for transfecting cells in vitro. In particular, cationic polymers and polynucleotide containing polyplexes comprising such polymers are provided..
10/09/14
20140302605
Method of obtaining a population of cells
A method of obtaining stromal progenitor cells (spc) from subcutaneous adipose tissue by incubation of a very small volume of the subcutaneous adipose tissue in an enzyme solution produces spc that are usable in medical applications based on autologous spc even on individuals having a body mass index lower than 18.5.. .
10/09/14
20140302601
Primitive and proximal hepatic stem cells
Hepatic progenitors comprise two populations of human hepatic stem cells, primitive and proximal hepatic stem cells, and two populations of committed progenitors, one for biliary cells and one for hepatocytes. Human primitive hepatic stem cells are a very small fraction of the liver cell population and give rise to proximal hepatic stem cells constituting a much larger fraction of the liver.
10/09/14
20140302599
Method of co-culturing mammalian muscle cells and motoneurons
The invention provides a method of co-culturing mammalian muscle cells and mammalian motoneurons. The method comprises preparing one or more carriers coated with a covalently bonded monolayer of trimethoxysilylpropyl diethylenetriamine (deta); suspending isolated fetal mammalian skeletal muscle cells in serum-free medium according to medium composition 1; suspending isolated fetal mammalian spinal motoneurons in serum-free medium according to medium composition 1; plating the suspended muscle cells onto the one or more carriers at a predetermined density and allowing the muscle cells to attach; plating the suspended motoneurons at a predetermined density onto the one or more carriers and allowing the motoneurons to attach; covering the one or more carriers with a mixture of medium composition 1 and medium composition 2; and incubating the carriers covered in the media mixture..
10/09/14
20140302597
Cell culture container, and automated cell subculture device and cell subculture method using same
Provided is a cell culture container that makes it possible to subculture cells without a dispensing operation using a pipette and also to prevent microbial contamination in the culture container during cell subculture. The cell culture container is provided, within a culture container (1) forming a sealable first culture zone, with a partition member (4) having a wall surface formed lower than the wall surface of the culture container and forming a second culture zone; and has means for raising and lowering the partition member while the culture container is in a sealed state.
10/09/14
20140302594
Cell culture assay
The present invention relates to a cell culture assay. The present invention comprises: a substrate; a scaffold channel which is formed along the centre inside the substrate, and of which at least one is disposed continuously, and inside which a scaffold flows; and a microfluidic channel or channels which is/are respectively formed on one side or on both sides of the scaffold channel, and inside which cells flow, and, here, a leak-preventing part for preventing the scaffold from leaking into the microfluidic channel(s) is formed in at least one of the ceiling surface and the floor surface of a boundary part of the scaffold channel and the microfluidic channel(s)..
10/09/14
20140302587
Process for producing cellulases using a filamentous fungus suitable for a fermenter, having a low volumetric oxygen transfer coefficient kla
A second step for growth and production in the presence of at least one inducer carbonaceous substrate in fed batch phase in the presence of a limiting flow of carbon source in the range 50 to 140 mg per gram of cells per hour.. .
10/09/14
20140302586
Variants of a family 44 xyloglucanase
The present invention relates to variants of a parent xyloglucanase. The present invention also relates to polynucleotides encoding the variant xyloglucanases and to nucleic acid constructs, vectors, and host cells comprising the polynucleotide..
10/09/14
20140302581
Methods for enhanced protein production
The present invention provides a method of increasing protein production in a cell culture by growing cells that produce the protein (e.g., the growth phase) in a perfusion cell culture to a high cell density (i.e., at least above about 40×106 cells/ml) and then switching to a protein production phase, wherein the cells are cultured in a fed-batch cell culture. The present invention further provides a method for clarifying a protein from a cell culture by adjusting the ph of the cell culture to below neutral ph (i.e., below a ph of 7) and settling the cell culture, such that the cell culture separates to form a supernatant layer and a cell-bed layer, wherein the protein is in the supernatant layer..
10/09/14
20140302574
3-hydroxypropionic acid and other organic compounds
Methods and materials related to producing 3-hp as well as other organic compounds are disclosed. Specifically, isolated nucleic acids, polypeptides, host cells, and methods and materials for producing 3-hp and other organic compounds are disclosed..
10/09/14
20140302564
Method for sterilizing microbial cells using polyethylene glycol-based nonionic surfactant
A method for sterilizing microbial cells is provided. According to the method, microbial cells or a culture containing microbial cells are treated with a polyethylene glycol-based nonionic surfactant so that almost all of the microbial cells are sterilized while the enzyme activity expressed in the microbial cells is maintained at a high level.
10/09/14
20140302563
Methods and compositions for controlling gene expression by rna processing
The present disclosure provides nucleic acids encoding an rna recognition sequence positioned proximal to an insertion site for the insertion of a sequence of interest; and host cells genetically modified with the nucleic acids. The present disclosure also provides methods of modifying the activity of a target rna, and kits and compositions for carrying out the methods..
10/09/14
20140302559
Rapid method for cloning and expression of cognate antibody variable region gene segments
In the method as reported herein the isolation of nucleic acid segments encoding antibody variable domains and the insertion of the isolated nucleic acid segments in eukaryotic expression plasmids is performed without the intermediate isolation and analysis of clonal intermediate plasmids. Thus, in the method as reported herein the intermediate cloning, isolation and analysis of intermediate plasmids is not required, e.g.
10/09/14
20140302557
Engineered lower eukaryotic host strains for recombinant protein expression
The present invention relates to novel engineered lower eukaryotic host cells for expressing heterologous proteins and to methods of generating such strains.. .
10/09/14
20140302556
Controlling o-glycosylation in lower eukaryotes
Lower eukaryote host cells in which expression of the endogenous protein mannosyltransferase 2 (pmt2) gene has been disrupted by introducing a nucleic acid molecule encoding a pmt2p protein having a mutation in a conserved region of the protein. The mutation confers to the host cell resistance to pmt inhibitors, which are used to reduce the amount of o-glycosylation of recombinant proteins produced by the host cells but which also have the effect of reducing the robustness of the host cells during fermentation.
10/09/14
20140302547
Methods of isolating bipotent hepatic progenitor cells
A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical mhc class i antigen(s) negative and icam-1 antigen positive. The weak or dull expression of nonclassical mhc class i antigen(s) can be used for further enrichment of hepatic progenitors.
10/09/14
20140302540
Blood sample assay method
The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component. The method includes: i) diluting the sample with a reagent mixture; ii) substantially removing blood cells; iii) using a reagent which serves to temporarily prevent reaction of the second component, to generate a blocked second component; iv) causing the selective reaction of a constituent of each analyte to directly or indirectly generate detectable reaction products, where one of the analytes is the first component; v) monitoring the detectable reaction product or products; vi) relating an amount of the detectable product or products and/or a rate of formation of the detectable product or products to the concentration of each analyte, where the concentration of at least the first component is related to a corresponding detectable reaction product by means of estimating an un-measurable (fictive) endpoint.
10/09/14
20140302529
Filtering particles from blood or other media
A filter element (200) and a method are disclosed for retaining particles of a medium, for example (rare) cells of blood. The filter element (200) comprises at least one opening (220) that (i) has an elongate cross section and/or (ii) has a cross section that decreases in flow direction (x) and/or (iii) is bordered by a transparent wall.
10/09/14
20140302526
Zap-70 detection in chronic lymphocytic leukemia
Detection of zap-70 expression provides important information about disease progression and overall survival in patients with chronic lymphocytic leukemia (cll). The invention provides methods for diagnosing cll in a subject, as well as methods for clearly distinguishing cll patients with aggressive form of the disease.
10/09/14
20140302522
Method for predicting the presence of reproductive cells in testis
The present invention relates to testicular germline markers and their use for predicting the presence or not of reproductive cells in testis of an infertile or hypo fertile male subject.. .
10/09/14
20140302515
Biomarkers for breast cancer patients
Kaiso, a transcriptional regulator with bimodal dna-binding specificity, is over-expressed in breast cancer cells, and its nuclear localization is correlated with malignant and lymph node metastasis. Depleted expression of kaiso in those cells results in a significant decrease in basal and egf-induced cell migration, and this is associated with increased e-cadherin expression.
10/09/14
20140302512
Genotoxicity testing
The present invention relates to methods for detecting for the presence of an agent that putatively causes or potentiates dna damage comprising subjecting a cell (containing a dna sequence encoding gaussia luciferase (gluc) reporter protein operatively linked to a human gadd45α gene promoter and a human gadd45α gene regulatory element arranged to activate expression of the dna sequence in response to dna damage) to an agent; and monitoring the expression of the gluc reporter protein from the cell. The invention also concerns expression cassettes, vectors and cells which may be used according to such a method and also modified media that may be employed in assays and in preferred embodiments of the method of the invention..
10/09/14
20140302511
Cancer stem cell-specific molecule
An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective of the present invention is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients.
10/09/14
20140302508
Dna polymerases with increased 3'-mismatch discrimination
Disclosed are mutant dna polymerases having increased 3′-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods.
10/09/14
20140302507
Dna polymerases with increased 3'-mismatch discrimination
Disclosed are mutant dna polymerases having increased 3′-mismatch discrimination relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods.
10/09/14
20140302483
Cell separation method
The present invention provides methods and compositions for separating cells from a sample containing erythrocytes. The method is for recovering desired cells from a sample containing the desired cells, erythrocytes and undesired cells comprising: a) contacting the sample with a composition, said composition comprising: i) an erythrocytes aggregation reagent ii) at least one antigen recognizing moiety coupled to a magnetic particle, wherein said particle with said at least one antigen recognizing moiety specifically binds to at least one antigen specific for one or more undesired cellular components; b) applying simultaneously i) gravity sedimentation for sedimentation of erythrocytes and ii) a magnetic field gradient to said sample for immobilizing said magnetic particle generating a pellet and a supernatant phase, and c) recovering the desired cells from the supernatant phase.
10/09/14
20140302482
Electromagnetic blood preservation and storage
Embodiments of the present invention include method, system and apparatus for storing fluids (including whole blood or any of the components thereof) to thereby enhance viability of the fluids being stored outside a living body. Embodiments of the present invention include, for example, exposing an electric, magnetic, electromagnetic, field or combinations thereof to one or more storage mediums containing the fluids.
10/09/14
20140302424
Mixed-metal platinum catalysts with improved carbon monoxide tolerance
Disclosed are catalysts, especially catalytic anodes, useful for catalyzing reactions in fuel cells and in other environments. The catalysts have a substrate base made of iridium and/or ruthenium.
10/09/14
20140302420
Ceramic anode materials for solid oxide fuel cells
Novel anode materials including various compositions of vanadium-doped strontium titanate (svt), and various compositions of vanadium- and sodium-doped strontium niobate (snnv) for low- or intermediate-temperature solid oxide fuel cell (sofcs). These materials offer high conductivity achievable at intermediate and low temperatures and can be used as the structural support of the sofc anode and/or as the conductive phase of an anode.
10/09/14
20140302417
Epoxy methacrylate based adhesive for fuel cell flow field plates
An electrically conductive adhesive is disclosed for bonding anode and cathode flow field plates together for use in fuel cells. The adhesive formulation comprises epoxy methacrylate resin and non-fibrous carbon particles but little to no carbon fibres.
10/09/14
20140302414
Integrated power generation and chemical production using fuel cells
In various aspects, systems and methods are provided for operating a molten carbonate fuel cell to reduce or minimize losses due to loss of heat energy. A molten carbonate fuel cell can be operated based on a desired ratio of heat generated by exothermic reactions in the fuel cell relative to heat consumed by endothermic reactions in the fuel cell and any optional integrated endothermic reaction stages..
10/09/14
20140302413
Integrated power generation and chemical production using fuel cells
In various aspects, systems and methods are provided for operating a molten carbonate fuel cell with an excess of reformable fuel relative to the amount of oxidation performed in the anode of the fuel cell. Instead of selecting the operating conditions of a fuel cell to improve or maximize the electrical efficiency of the fuel cell, an excess of reformable fuel can be passed into the anode of the fuel cell to increase the chemical energy output of the fuel cell.
10/09/14
20140302409
Fuel system for fuel cells
Fuel cell structure and method of producing electrical energy from a methanol-based initial material. The fuel cell structure is comprised of a fuel cell for decomposing hydrocarbon-based fuel in order to produce electrical energy, a fuel tank from which fuel can be fed into the fuel cell, and a treatment unit for decomposition products, into which unit it is possible to direct the decomposition products of the fuels.
10/09/14
20140302408
Additives for hydrogen/bromine cells
The invention relates to the use of 1-alkyl-2-alkyl pyridinium halide (e.g., 1-ethyl-2-methyl pyridinium bromide), 1-alkyl-3-alkyl pyridinium halide (e.g., 1-ethyl-3-methyl pyridinium bromide) or 1-alkyl-3-alkyl imidazolium halide (e.g., 1-butyl 3-methyl imidazolium bromide) as additives in an electrolyte used in hydrogen/bromine cells, for complexing the elemental bromine formed in such cells. The invention also provides an electrolyte comprising aqueous hydrogen bromide and said additives, and processes for operating an electrochemical flow cell selected from the group consisting of hydrogen/bromine or vanadium/bromine cells..
10/09/14
20140302406
Electrode mesh galvanic cells
The present invention is directed to the fabrication of thin aluminum anode batteries using a highly reproducible process that enables high volume manufacturing of the galvanic cells. A thin aluminum anode galvanic cell having a meshed structure is provided which includes a catalytic metal layer positioned on a patterned silicon substrate, an etched dielectric layer positioned to cover the catalytic metal layer, the catalytic metal layer serving as an etch stop for the etched dielectric layer and an etched aluminum layer positioned to cover the dielectric layer, the dielectric layer serving as an etch stop for the etched aluminum layer..
10/09/14
20140302403
Non-aqueous electrolyte for rechargeable magnesium ion cell
A non-aqueous magnesium electrolyte comprising: (a) at least one organic solvent; (b) at least one electrolytically active, soluble, inorganic magnesium (mg) salt complex represented by the formula: mgazbxc wherein a, b, and c are selected to maintain neutral charge of the molecule, and z and x are selected such that z and x form a lewis acid, and 1≦a≦10, 1≦b≦5, and 2≦c≦30. Further z is selected from a group consisting of aluminum, boron, phosphorus, titanium, iron, and antimony; x is selected from the group consisting of i, br, cl, f and mixtures thereof.
10/09/14
20140302402
Nonaqueous electrolyte compositions
Electrolyte compositions comprising fluorinated acyclic carboxylic acid esters, fluorinated acyclic carbonates, and/or fluorinated acyclic ethers; co-solvents; and certain film-forming chemical compounds are described. The electrolyte compositions are useful in electrochemical cells, such as lithium ion batteries where they provide the improved performance of a combination of high capacity and high cycle life..
10/09/14
20140302401
Nonaqueous electrolyte compositions
Electrolyte compositions comprising fluorinated acyclic carboxylic acid esters, fluorinated acyclic carbonates, and/or fluorinated acyclic ethers; co-solvents; and certain film-forming chemical compounds are described. The electrolyte compositions are useful in electrochemical cells, such as lithium ion batteries where they provide the improved performance of a combination of high capacity and high cycle life..
10/09/14
20140302398
Polyurethane-based electrode binder compositions and electrodes thereof for electrochemical cells
The invention relates to an electrode binder composition, an electrode made using the described binder composition, and an electrochemical cell made using the described electrode, where the all of these materials are made using a composition of a poly(dialkylene ester) thermoplastic polyurethane composition. The electrode is made using the described thermoplastic polyurethane and an electrode active material.
10/09/14
20140302393
High capacity lithium-ion electrochemical cells and methods of making same
High capacity lithium-ion electrochemical cells are provided that include positive electrode comprising a layered lithium transition metal oxide having a first irreversible capacity and a negative electrode that includes an alloy anode material that also has a first irreversible capacity. The first irreversible capacity of the positive electrode is less than the first irreversible capacity of the negative electrode.
10/09/14
20140302377
Battery pack for electric power tool
A contact diameter, which is formed by a cell holding portion and receiving-partitioning portions, is configured to be smaller than the diameter of a columnar outer peripheral surface of a battery cell. The cell holding portion comes into contact with the columnar outer peripheral surface of the battery cell so as to hold the columnar outer peripheral surface.
10/09/14
20140302364
Battery module
A battery module has a cell unit including battery cells, a positive external terminal electrically connected to a positive side of the battery cells through a positive electro conductive member, and a negative external terminal electrically connected to a negative side of the battery cells. The positive electro conductive member extends a first surface which is one of surfaces of the cell unit.
10/09/14
20140302360
Electrical energy accumulator
An electrical energy accumulator and a method for manufacturing an electrical energy accumulator. Such an electrical energy accumulator, in particular, for an electric vehicle, has a plurality of battery cells which are electrically connected to one another.
10/09/14
20140302357
Battery module
A battery module has a cell unit including battery cells and a battery monitoring element attached to the cell unit. The battery cells are arranged in a first direction.
10/09/14
20140302356
Battery module
A battery module includes a cell unit, a first end plate, and a binding band. The cell unit includes a plurality of battery cells arranged in a first direction.
10/09/14
20140302352
Capacitive communication layer for cell integrated battery management system
A battery module that includes a plurality of battery cells having cell elements that are electrically coupled. Each cell includes a first capacitor plate pair having a first capacitor plate and a second capacitor plate at a first side of the cell element.
10/09/14
20140302181
Drug screening method, drugs promoting extracellular matrix crosslinking and the applications thereof
The present invention discloses a drug screening method, drugs promoting extracellular matrix protein crosslinking and their applications, the said drug screening method, is used to screen out materials promoting the expression of loxl1 gene, wherein, the said drug screening method contains the following steps: a, construct the 2nd generation lentiviral vector used to control the zsgreen expression by human loxl 1 gene promoter. B, infect human fibroblasts with the 2nd generation lentiviral vector, and construct the new human fibroblasts which integrate ploxl1-zsgreen components.
10/09/14
20140302163
Water with improved transdermal and cellular delivery properties and methods of manufacture and use thereof
A process for preparing conventional water sources for providing “ideal state” cellular wellness benefits via topical hydration and natural transdermal, epithelial or epicellular absorption. The invention's process considers preconditioned water sources that have removed solids, dissolved solids, contaminants—both organic and inorganic and subsequently the method purifies the water respective of removing pathogens, and structures the water for cellular uptake in the form of vicinal grade water, with improved characteristics of ideal frequency, cluster size, ph, before safely introducing negative orp (highly ionized state) to the water structure and organic nutrients or other supplemental pharmaceutical grade organic materials onto the skin or epithelial/epicellular environments surrounding tissue and cells..
10/09/14
20140302155
Production of a human beta cell line from an early post natal pancreas
The present invention relates to a method for preparing commercial scale quantities of human functional beta cells and to the establishment of cell lines from non-foetal pancreatic tissues. It also relates to a method of diagnosis using beta cell tumors or cells derived thereof.
10/09/14
20140302130
Silica-matrix forming compositions, materials formed therefrom, and methods of using the same
The present invention provides compositions for encapsulation of biomaterials in a silica-matrix. The present invention also provides methods of making silica-matrix encapsulated biomaterials, and to methods of using silica-matrix encapsulated biomaterials.
10/09/14
20140302124
Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of influenza virus infection
Influenza virus infection and the resulting complications are a significant global public health problem and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Improving humoral immunity to influenza is the target of current conventional influenza vaccines, however, these are generally not cross-protective.
10/09/14
20140302123
Products useful for the treatment of malignant neoplasms of the human nervous system
The application provides products, which may trigger pro-apoptotic or pro-death effects on neoplastic cells and/or tissues of the human nervous system, more particularly on neoplastic cells and/or tissues of the human cns. The products of the application can be used as anti-proliferative or tumoricid agents in the treatment and/or palliation and/or prevention of neoplasms of the human nervous system, more particularly of glioblastoma or brain stem glioma.
10/09/14
20140302116
Compositions and methods for nucleic acid delivery
The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof. In some embodiments, a structure includes a substrate; and a multilayer film coated on the substrate, wherein adjacent layers of the multilayer film are associated with one another via one or more non-covalent interactions, wherein the multilayer film comprises a first nucleic acid agent present at a loading density, and further wherein the multilayer film is characterized in that, when the structure is placed on a subject so that the multilayer film contacts cells, the first nucleic acid agent is released with a profile characterized by a feature selected from the group consisting of 1) being a burst-free release; 2) being a sustained release; and 3) exhibiting in vitro and/or in vivo biological effectiveness..
10/09/14
20140302097
Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
Compositions comprising dendritic cells pulsed with tumor lysate and at least one toll-like receptor (tlr) ligand which may be used for eliciting a specific immune response in a mammal in need thereof for treating diseases including a tumor are disclosed. Also disclose are methods of activating dendritic cells, comprising providing at least one toll-like receptor (tlr) ligand; and pulsing a dendritic cell with the at least one tlr ligand.
10/09/14
20140302096
Compositions for the preparation of mature dendritic cells
The invention relates to a method for in vitro maturation of at least one immate dendritic cell, comprising stimulating said immature dendritic cell with tnfα, il-1β, ifnγ, a tlr7/8 agonist and prostaglandin e2(pg). Furthermore, the invention elates to a composition comprising these factors as well as to mature dendritic cells produced by a method of the invention..
10/09/14
20140302088
Compositions and methods for dengue virus chimeric constructs in vaccines
Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition.
10/09/14
20140302082
Nucleic acid construct comprising nucleic acid derived from genome of hepatitis c virus of genotype 1b, hepatitis c virus genome-replicating cells transfected with the same, and method for producing infectious hepatitis c virus particles
A subgenomic replicon rna (nucleic acid) having an excellent autonomously replicating ability and a fullgenomic replicon rna (nucleic acid) having an excellent autonomously replicating ability and infectious hcv particle-producing ability, each derived from a novel hcv of genotype 1b, are provided. Particularly, a subgenomic replicon rna (nucleic acid) and a fullgenomic replicon rna (nucleic acid), each derived from an hcv genome of the nc1 strain which is a novel hcv genotype 1b isolated from a patient with acute severe hepatitis c, are provided..
10/09/14
20140302076
Immunogenic compositions and methods therefor
The present invention provides compositions relating to viral capsomeres which comprise foreign immunogenic sequences for use in pharmaceutical compositions and methods of producing such compositions, and related isolated or purified protein and nucleic acid molecules, vectors, host cells, compositions, and methods of use to augment an immune response, immunise an animal and prophylactically or therapeutically treat a disease, disorder or condition. The viral capsomere may be derived from a polyomavirus and comprise an immunogen of interest at the n-terminus and further at the c-terminus and/or at one or more exposed loops of the capsomere..
10/09/14
20140302072
Non-natural mic proteins
This invention describes soluble, monovalent, non-natural protein molecules that can activate nk cells and certain t-cells to attack specific cellular target cells by attaching the nkg2d-binding portions of monovalent mica or micb protein, i.e. Their α1-α2 platform domain, to the intended target cell specifically.
10/09/14
20140302064
Optimized anti-cd3 variable regions
The present invention is directed to optimized anti-cd3 variable sequences for use in a variety of bispecific formats, including those that utilize scfv components. The invention further relates to nucleic acids encoding for the polypeptide, to vectors comprising the same and to host cells comprising the vector.
10/09/14
20140302059
Compositions and methods for cancer and cancer stem cell detection and elimination
In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded rna-specific adenosine deaminases, or adar, enzymes.
10/09/14
20140302052
Combination therapy to enhance nk cell mediated cytotoxicity
The function of natural killer (nk) cells is regulated by inhibitory and activating signals delivered by cell surface receptors, 1-7f9 is a fully human monoclonal antibody (mab) directed against kir2dl1 and k1r2dl2/3 receptors that blocks its interaction with its hla-c ligands breaking nk cell tolerance to autologous tumor ceils. Lεnalidomide has been shown to increase nk cell cytotoxicity in vitro.
10/09/14
20140302050
Targeting an amphiregulin-derived cell surface neo-epitope
Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies..
10/09/14
20140302037
Bispecific-fc molecules
Described herein is a bispecific molecule containing an fc polypeptide chain and immunoglobulin variable regions. Also provided are pharmaceutical formulations comprising such molecules, nucleic acids encoding such molecules, host cells containing such nucleic acids, methods of making such molecules, and methods of using such molecules..
10/09/14
20140302033
Albumin binding antibodies and binding fragments thereof
A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in seq id no: 1 or seq id no:2 and/or comprising a light chain variable domain having the sequence given in seq id no:3 or seq id no:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in seq id no: 1 and seq id no:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in seq id no: 2 and seq id no:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides.
10/09/14
20140302025
Vegf-binding protein for blockade of angiogenesis
Provided are chimeric vegf-binding proteins and nucleic acids (e.g., a vector) encoding chimeric vegf-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric vegf-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric vegf-bind ing protein..
10/09/14
20140302020
Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma, ovarian carcinoma, pancreatic carcinoma, and colorectal carcinoma.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cells for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cells with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.7495

6287

2 - 1 - 148